Followers | 72 |
Posts | 4273 |
Boards Moderated | 2 |
Alias Born | 08/21/2015 |
![](https://investorshub.advfn.com/uicon/539882.png?cb=1685574163)
Wednesday, September 23, 2020 11:57:11 AM
Sep 23, 2020, 11:39 ET
NEW YORK , Sept. 23, 2020 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NEO: MMED)(OTCQB: MMEDF ), the leading neuro-pharmaceutical company for psychedelic inspired medicines announces, at the request of IIROC on behalf of the NEO Exchange, that MindMed's management is unaware of any material change in MindMed's operations that would account for the recent increase in market activity.
About MindMed
Mind Medicine (MindMed) Inc. is a neuro-pharmaceutical company that discovers, develops, and deploys psychedelic-inspired medicines to improve health, promote wellness, and alleviate suffering. The company is assembling a compelling drug development pipeline of innovative treatments through human clinical trials to help patients with mental and behavioral health issues, including substance use disorder. The MindMed executive team brings extensive biopharmaceutical industry experience to this groundbreaking approach to the development of next-generation psychedelic medicines. MindMed trades on the NEO Exchange under the symbol MMED. MindMed can also be traded in the US under the symbol OTC: MMEDF and in Germany under the symbol DE:MMQ. For more information: www.mindmed.co .
MindMed Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and performance of MindMed, and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, MindMed's and its collaborators' ability to continue to conduct research and clinical programs, MindMed's ability to manage its supply chain, product sales of products marketed by MindMed and/or its collaborators (collectively, "Products"), and the global economy; the nature, timing, and possible success and therapeutic applications of Products and Product candidates and research and clinical programs now underway or planned; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Product candidates and new indications for Products; unforeseen safety issues resulting from the administration of Products and Product candidates in patients, including serious complications or side effects in connection with the use of MindMed's Products and product candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict MindMed's ability to continue to develop or commercialize Products; ongoing regulatory obligations and oversight impacting Products, research and clinical programs, and business, including those relating to patient privacy; uncertainty of market acceptance and commercial success of Products and Product candidates and the impact of studies on the commercial success of Products and Product candidates; the availability and extent of reimbursement of Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; competing drugs and product candidates that may be superior to Products and Product candidates; the extent to which the results from the research and development programs conducted by MindMed or its collaborators may be replicated in other studies and lead to therapeutic applications; the ability of MindMed to manufacture and manage supply chains for multiple products and product candidates; the ability of MindMed's collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labelling, distribution, and other steps related to MindMed's Products and product candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of MindMed to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license or collaboration agreement to be cancelled or terminated without any further product success; and risks associated with intellectual property of other parties and pending or future litigation relating thereto, other litigation and other proceedings and government investigations relating to MindMed and its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on MindMed's business, prospects, operating results, and financial condition. Any forward-looking statements are made based on management's current beliefs and judgment. MindMed does not undertake any obligation to update publicly any forward-looking statement.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States . The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act)
Media Contact: [email protected]
Investor Relations: [email protected]
SOURCE Mind Medicine (MindMed) Inc.
Related Links
https://www.mindmed.co
Recent MNMD News
- MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT) • Business Wire • 07/17/2024 11:00:00 AM
- MindMed to be Included in Russell 2000® and Russell 3000® Indexes • Business Wire • 06/28/2024 11:00:00 AM
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • Business Wire • 06/21/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/20/2024 12:00:10 PM
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD) • Business Wire • 06/20/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/11/2024 08:30:10 PM
- MindMed to Participate in June Conferences • Business Wire • 05/28/2024 11:00:00 AM
- MindMed to Participate at May Investor Conferences • Business Wire • 05/09/2024 08:01:00 PM
- New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US • Business Wire • 05/09/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/08/2024 08:15:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:10:12 PM
- MindMed Reports First Quarter 2024 Financial Results and Business Updates • Business Wire • 05/08/2024 08:01:00 PM
- MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York • Business Wire • 05/04/2024 12:00:00 PM
- MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update • Business Wire • 05/02/2024 11:00:00 AM
- MindMed to Present at Upcoming May Medical Conferences • Business Wire • 04/25/2024 11:00:00 AM
- MindMed to Present at Upcoming April Medical Conferences • Business Wire • 04/02/2024 11:00:00 AM
- MindMed Announces Voluntary Delisting from Cboe Canada • Business Wire • 04/01/2024 09:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 12:32:03 PM
- MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference • Business Wire • 03/11/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 01:19:43 PM
- Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement • Business Wire • 03/07/2024 12:13:00 PM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 03/07/2024 12:09:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:56:00 AM
- MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder • Business Wire • 03/07/2024 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/01/2024 06:56:37 PM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM